News and Announcements
Novapep now has a complete Peptide Mimetic of Activated Protein C
- Published March 12, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Prof John Griffin of the Scripps Research Institute and a co-founder of Novapep has a developed a linked form of P1, which Novapep licensed in 2017, and P3. The bivalently linked peptide is called G10 and it generates synergistic anti-inflammatory and cytoprotective cell-signalling which is significantly greater than co-administered P1 and P3.
The Company has licensed the G10 PCT patent from the Scripps and Novapep has also filed a use patent for P1 in inflammatory skin disorders.
In 2020, Novapep undertook a P1 in atopic dermatitis study which showed that the P1 efficacy was as good as cortico steroids, but with none of the side effects. Professor Richard Payne, Novapep’s Chief Scientific Officer, is currently undertaking a study of G10 in atopic dermatitis and Professor Stuart Brierley will undertake animal studies of G10 in anti-inflammatory and analgesic colitis models of inflammatory bowel disease in Q2/2021.
Novapep is currently raising $500,000 on a pre-money valuation of $4.5 million to fund animal studies and regulatory activities towards a Phase 1 trial.
About Novapep Pty Ltd
Novapep was founded by Prof John Griffin of The Scripps Research Institute, San Diego and Jay Hennock, founder and CEO of Bioatrix, Sydney to develop new peptide structures, which are anti-inflammatory, cytoprotective and analgesic for the treatment of atopic dermatitis and psoriasis/inflammatory skin disorders (‘ISD’) and inflammatory bowel disease/irritable bowel syndrome (‘IBD’). Prof Richard Payne, University of Sydney, has recently become Novapep’s Chief Scientific Officer.
Novapep has been approached by two global pharmaceutical companies wishing to explore partnering/out-licensing. Before entering negotiations, the Company is seeking $500,000 to secure additional patents and animal study data.
Company Updates
The Billion-Dollar Blind Spot: The Australian Tech Making ‘Invisible’ Decay a Visible Asset for Investors
Incisive Technologies is moving dentistry from “restorative” to “preventative.” By detecting decay at 30 microns—long before it appears on an X-ray—their FDA-approved BlueCheck tool is eliminating the industry’s “watch and wait” mantra and opening a massive new frontier for clinical and at-home oral health monitoring.
How to Target Wholesale Investors in Australia
Targeting wholesale investors effectively means going beyond the legal definition of who qualifies and understanding who is actually likely to invest in your specific opportunity. Australia has a substantial and growing wholesale investor community, but it is not homogeneous. The investors who back seed-stage biotech companies are not the same investors who deploy into private […]
Wholesale Investor Email List: Why Quality Beats Quantity
When founders search for a wholesale investor email list, what they actually need is access to investors who are actively looking to deploy capital into private market opportunities. The distinction matters because a raw list of email addresses and a curated network of engaged wholesale investors produce fundamentally different results. This article explains why opt-in […]
Backed By Leading Investment Groups and Family Offices
